Virus injection halts pancreatic tumor growth in trial

May 29, 2026

Iniulat ng AI

A genetically engineered virus has stopped pancreatic tumors from growing in three patients in an early US clinical trial. The results come from a safety study led by researchers at the University of Minnesota.

The first patient received the treatment a year ago after diagnosis of a 7-centimeter tumor confined to the pancreas. The other two patients were treated later, and all three remain alive with stable disease, according to Masato Yamamoto, who led development of the therapy. Only one-tenth of the planned dose was used in this initial phase, yet tumors have not spread or enlarged since injection.

Mga Kaugnay na Artikulo

A volunteer receiving a needle-free vaccine in a lab with AI-designed virus models in the background.

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

June 05, 2026 Iniulat ng AI Larawang ginawa ng AI Fact checked

A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.

Engineered phages redirect vaccine immunity to eradicate tumors in mice

Researchers have used genetically modified phages to harness pre-existing vaccine immunity and destroy cancer cells in mice. The approach eradicated tumors in 44 percent of treated animals with no recurrence after a year.

Sugar-coated nanoparticles boost glioblastoma survival in mice

July 17, 2026 Iniulat ng AI

Researchers at Oregon State University have developed an experimental treatment that uses sugar-coated nanoparticles to deliver genetic material across the blood-brain barrier in a mouse model of glioblastoma. The approach restored a tumor-suppressing protein and increased median survival by 50 percent while shrinking tumors without measurable organ toxicity.

Kalusugan

Experimental mRNA vaccine shows protection against multiple ebola viruses

Kalusugan

FDA-approved drug shows promise against rare liver cancer

Kalusugan

New drug Daraxonrasib nearly doubles survival in pancreatic cancer trial

McGill researchers use reversible drug approach to boost natural killer cells against hard-to-treat cancers

Researchers at McGill University report a drug-based method to temporarily enhance natural killer (NK) cells—an immune cell type—by inhibiting two proteins, improving the cells’ ability to attack several aggressive cancers in preclinical experiments.

USC scientists create renewable supply of cancer-fighting cells

June 29, 2026 Iniulat ng AI

Researchers at USC Stem Cell have developed a method to produce large numbers of immune cell precursors that can be engineered to target cancer. The approach, published in the journal Cell, uses granulocyte-monocyte progenitors that self-renew in the laboratory.

CAR-T cell therapy shows early promise for HIV control

A small study has found that CAR-T cell therapy may offer a new way to manage HIV over the long term. The approach, already used to treat certain cancers, involves engineering a patient’s own immune cells.

July 26, 2026 11:32